Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 723 JPY 7.59% Market Closed
Market Cap: 10.6B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Perseus Proteomics Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Income from Continuing Operations
-ÂĄ1.1B
CAGR 3-Years
-39%
CAGR 5-Years
-47%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Income from Continuing Operations
ÂĄ5.4B
CAGR 3-Years
51%
CAGR 5-Years
51%
CAGR 10-Years
N/A
PeptiDream Inc
TSE:4587
Income from Continuing Operations
ÂĄ17.1B
CAGR 3-Years
40%
CAGR 5-Years
46%
CAGR 10-Years
64%
Takara Bio Inc
TSE:4974
Income from Continuing Operations
ÂĄ145m
CAGR 3-Years
-79%
CAGR 5-Years
-49%
CAGR 10-Years
-22%
Pharma Foods International Co Ltd
TSE:2929
Income from Continuing Operations
ÂĄ3.2B
CAGR 3-Years
-6%
CAGR 5-Years
45%
CAGR 10-Years
80%
C
Cuorips Inc
TSE:4894
Income from Continuing Operations
-ÂĄ632.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
10.3B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
719.16 JPY
Overvaluation 1%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Income from Continuing Operations?
Income from Continuing Operations
-1.1B JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Income from Continuing Operations amounts to -1.1B JPY.

What is Perseus Proteomics Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-47%

Over the last year, the Income from Continuing Operations growth was -40%. The average annual Income from Continuing Operations growth rates for Perseus Proteomics Inc have been -39% over the past three years , -47% over the past five years .

Back to Top